Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Original articles
Rentschler R, Wilbur D: Pyridoxine: a potential local antidote for mitomycin-C extravasation. J Surg Oncol 37: 269–271, 1988.
Argenta LC, Manders EK: Mitomycin C extravasation injuries. Cancer 51: 1080–1082, 1983.
Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.
Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.
Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.
Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.
Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.
Khanna AK, Khanna A, Asthana AK, et al: Mitomycin C extravasation ulcers. J Surg Oncol 28: 108–110, 1985.
Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.
Fuller B, Lind M, Bonomi P: Mitomycin C extravasation exacerbated by sunlight. Ann Intern Med 94: 542, 1981.
Moertel CG, Reitemeier RJ, Hahn RG: Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204: 111–114, 1968.
Alberts DS, Dorr RT: Case report: topical DMSO for mitomycin-C-induced skin ulceration. Oncol Nurs Forum 18: 693–695, 1991.
Aizawa H, Tagami H: Delayed tissue necrosis due to mitomycin C. Acta Derm Venereol 67: 364–366, 1987.
Herrera D, Burnham N: DMSO and extravasation of mitomycin. Oncol Nurs Forum 16: 155, 1989.
Wood HA, Ellerhorst-Ryan JM: Delayed adverse skin reactions associated with mitomycin-C administration. Oncol Nurs Forum 11: 14–18, 1984.
Bartkowski-Dodds L, Reville B: Extensive tissue ulceration due to apparent sensitivity reactions to mitomycin. Cancer Treat Rep 69: 925–927, 1985.
Secondary literature
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Krämer I: Onkologische Pharmazie. In: Jaehde U, Radziwill R, Mühlebach S, et al (eds) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mbH, 1st edition: 268–269, 1998.
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Gain M, Melzer S, Meyer-Jürshof A, et al: Mitomycin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: 35, 1997.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guidelines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.
Further reading
Averbuch SD, Boldt M, Gaudiano G, et al: Experimental chemotherapy-induced skin necrosis in swine. J Clin Invest 81: 142–148, 1988.
Dorr RT, Soble MJ, Liddil JD, et al: Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dim-ethyl sulfoxide. J Clin Oncol 4: 1399–1404, 1986.
Hahn SM, Sullivan FJ, De Luca AM, et al: Protection of mitomycin C induced skin extravasation with the nitroxide, 3-carbamoyl-proxyl (3CP). Int J Oncol 10: 119–123, 1997.
Ignoffo RJ, Tomlin W, Rubinstein E, et al: A model for skin toxicity of antineoplastic drugs: doxorubicin (DOX), mitomycin-C (MMC), and vincristine (VCR). Clin Res 29: 437A, 1981.
Johnston-Early A, Cohen MH: Mitomycin C-induced skin ulceration remote from infusion site. Cancer Treat Rep 65: 529, 1981.
Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Mitomycin C. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_37
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3710-9_37
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3712-3
Online ISBN: 978-3-7091-3710-9
eBook Packages: Springer Book Archive